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Abstract: Iron overload (IOL) due to increased intestinal iron absorption constitutes a major clinical
problem in patients with non-transfusion-dependent thalassemia (NTDT), which is a cumulative
process with advancing age. Current models for iron metabolism in patients with NTDT suggest
that suppression of serum hepcidin leads to an increase in iron absorption and subsequent release
of iron from the reticuloendothelial system, leading to depletion of macrophage iron, relatively low
levels of serum ferritin, and liver iron loading. The consequences of IOL in patients with NTDT are
multiple and multifactorial. Accurate and reliable methods of diagnosis and monitoring of body iron
levels are essential, and the method of choice for measuring iron accumulation will depend on the
patient’s needs and on the available facilities. Iron chelation therapy (ICT) remains the backbone
of NTDT management and is one of the most effective and practical ways of decreasing morbidity
and mortality. The aim of this review is to describe the mechanism of IOL in NTDT, and the clinical
complications that can develop as a result, in addition to the current and future therapeutic options
available for the management of IOL in NTDT.
Keywords: non-transfusion dependent thalassemia; iron overload; iron chelation therapy; serum
ferritin; liver iron concentration
1. Introduction
Thalassemia is an inherited autosomal recessive hemoglobin disorder. At the molecular level,
these disorders stem from a defect either on chromosome 11 (encoding the β chain globin) or on
chromosome 16 (encoding the α chain globin) leading to myriad phenotypes (β-thalassemia and/or
α-thalassemia, respectively) [1]. Over the years, study of the thalassemia syndromes has served as a
paradigm for gaining insights into the cellular and molecular biology, as well as the pathophysiology,
of inherited genetic disorders. Most patients with thalassaemia are born in resource-poor countries,
but modern migration patterns have altered the epidemiology of this disease, and patients with
thalassaemia are now found in areas such as Europe and North America.
The disease hallmarks of thalassemia include an imbalance in the α/β-globin chain ratio, leading
to ineffective erythropoiesis, chronic haemolytic anaemia, and iron overload. These pathophysiological
mechanisms lead to an array of clinical manifestations involving numerous organ systems.
The degree of transfusion dependence is one of the elements considered in a recent classification of
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thalassemic disorders into transfusion-dependent thalassemia (TDT) and non-transfusion dependent
thalassemia (NTDT).
The NTDT class comprises several thalassemia syndromes, including β-thalassemia intermedia
(β-TI), hemoglobin H disease, and mild-to-moderate forms of hemoglobin E/β-thalassemia. Though
they are transfusion independent, patients with NTDT can still require transfusion therapy sporadically,
or even regularly, for the prevention or management of certain disease manifestations. Iron overload
(IOL) is one of the main culprits of disease-related morbidity in NTDT. It is one of the most prominent
clinical manifestations in NTDT. Iron overload in NTDT patients is a cumulative process with
advancing age, and concerns over secondary morbidities start beyond the ages of 10–15 years [1–5].
Despite receiving no or only occasional blood transfusions, patients with NTDT have increased
intestinal iron absorption, and can accumulate iron to levels comparable with TDT patients. This iron
accumulation occurs more slowly in NTDT patients compared to TDT patients, and contributes in some
way to the severity of some complications [3]. The understanding of the underlying pathophysiological
mechanisms of IOL in NTDT and its associated clinical morbidity has increased in recent years.
This new knowledge, in addition to the increasing awareness of the limitations of current ICT strategies,
is driving research into seeking novel therapeutic options for these patients, with amelioration of
ineffective erythropoiesis and iron dysregulation as the key targets for patients with NTDT. The aim
of this review is to describe the mechanism of IOL in NTDT, and the clinical complications that can
develop as a result, and the current and future therapeutic options for the management of IOL in NTDT.
2. Mechanism of Iron Overload (IOL) in Non-Transfusion-Dependent Thalassemia (NTDT)
The mechanism of increased intestinal iron absorption in NTDT patients is triggered by a cascade
that is initiated by ineffective erythropoiesis [6,7]. The conditions of anemia and hypoxia that result
from ineffective erythropoiesis influence the expression of the serum protein hepcidin, which is
the main regulator of intestinal iron absorption in the body [8,9]. Hepcidin negatively regulates
iron absorption because it downregulates the expression ferroportin, a transmembrane protein
responsible for iron absorption from the gastrointestinal tract and for exporting intracellular iron
into circulation [10]. Hepcidin levels decline when iron sequestration for erythropoiesis increases [8],
and this, in turn, results in upregulated ferroportin. High levels of ferroportin will then cause an
increased release of iron from the reticuloendothelial system, leading to depletion of macrophage
iron [11,12]. The downregulation of hepcidin in NTDT can also be mediated by growth differentiation
factor-15 (GDF-15) [11,13,14] and twisted gastrulation factor [15]. New studies have highlighted the
role of GDF-15 in creating the state of iron overload in NTDT. GDF-15 is a member of the transforming
growth factor-β (TGF-β) family and is normally upregulated during ineffective erythropoiesis, causing
the downregulation of hepcidin. Since NTDT is a disease of ineffective erythropoiesis, high blood
levels of GDF-15 have been noted is these patients [16]. Figure 1 portrays the mechanism of IOL
in NTDT.
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Figure 1. Iron overload mechanism in non-transfusion-dependent thalassemia. GDF-15: growth 
differentiation factor-15; TWGF-1: twisted gastrulation factor-1; HIFs: hypoxia inducible transcription 
factors; TMPRSS6: transmembrane protease, serine 6. (↑: increase; ↓: decrease). 
Figure 1. Iron overload mechanism in non-transfusion-dependent thalassemia. GDF-15: growth
differentiation factor-15; TWGF-1: twisted gastrulation factor-1; HIFs: hypoxia inducible transcription
factors; TMPRSS6: transmembrane protease, serine 6. (↑: increase; ↓: decrease).
Int. J. Mol. Sci. 2017, 18, 2778 3 of 9
3. Diagnosis and Quantification of IOL
Several modalities are currently available for the diagnosis and monitoring of IOL in NTDT,
each carrying their own advantages and disadvantages. Serum ferritin (SF) assessment is widely
available and is heavily relied upon in resource-poor countries [17]. Moreover, the assessment of
serial SF concentrations can also be a good indicator of iron chelator effectiveness [18]. SF levels,
however, are lower in NTDT than TDT for the same degree of hepatic iron concentration, and thus
they underestimate the iron burden [19]. In NTDT patients, SF values of >800 µg/L and <300 µg/L
are associated with an increased and absence of risk for morbidity, respectively [1,4]. Non-invasive
iron monitoring using R2 or T2* techniques by MRI has replaced liver biopsy as the gold standard for
the quantification of liver iron concentration (LIC) given its safety and reliability. In NTDT patients,
LIC values >5 mg/g are associated with increased morbidity, supporting the recommendation of ICT
initiation in patients with LIC levels >5 mg/g [20]. As per the available guidelines, assessment of
LIC should be performed every 6, 12, or 24 months [1]. This will depend on the severity of the iron
overload. Moreover, results from the ORIENT study revealed that patients with SF ≥800 µg/L have a
higher incidence of morbidities over 11 years [4]. Based on a ROC analysis, a SF level of ≥800 µg/L
had the highest accuracy for predicting LIC ≥5 mg Fe/g dry weight (dw) [21].
4. Morbidities Secondary to IOL
NTDT is associated with a high morbidity profile that can start manifesting as early as 10 years of
age [22]. Increased iron burden and accumulation underlies some of the complications seen in NTDT,
and contributes to their severity. This iron burden promotes oxidative damage in a variety of organs,
inducing a variety of endocrine and end organ dysfunction [23]. In the liver, chronic iron deposition is
detrimental to hepatocytes and can result in fibrosis, cirrhosis and eventually hepatocellular carcinoma [24].
Furthermore, endocrine glands have a high sensitivity for iron toxicity, and thus, iron deposition in these
glands (thyroid, parathyroid, testicles, pancreas etc.) may result in hypothyroidism, hypoparathyroidism,
hypogonadism, and diabetes mellitus type 1, respectively [2,3,22,25,26]. Kidneys are also affected
by iron overload, and this can manifest as both proteinuria and glomerular hyperfiltration as a
consequence of tubulointerstitial and glomerular damage, and patients can be at risk of end-stage
renal disease [27]. Iron overload, in addition to nutritional imbalance and increased erythron (due to
ineffective erythropoiesis), can also lead to osteoporosis, osteopenia, and other low bone mineral
density states in patients with NTDT [28,29]. There is also evidence for an association between IOL
and vascular disease in NTDT patients. Increased LIC was associated with a higher prevalence
of thrombosis and pulmonary hypertension in a cross-sectional analysis of β-TI patients, and in
splenectomized adults, there is a relationship between IOL and cerebrovascular disease [30,31].
However, we now know that in NTDT patients, hypercoagulability is the main contributor in the
development of vascular complications. Finally, IOL cardiomyopathy is a rare complication of NTDT
and is more routinely associated with TDT [32]. The phenotypic diversity of NTDT results from its
underlying genetic diversity, which can be explained by primary, secondary or tertiary modifiers [33,34].
Because of this, the amount of iron accumulation could vary across different genotypes, thus not only
affecting the frequency, but also the severity of IOL-related morbidities.
5. Iron Chelation Therapy
Despite all the recent advances in the understanding of pathophysiology and the development
of new novel therapies, iron chelation therapy (ICT) remains the backbone of NTDT management,
and is one of the most effective and practical ways to decrease morbidity and mortality [23]. Today,
the primary goal of ICT has shifted from treating or rescuing IOL to maintaining safe levels of body
iron at all times [18]. To achieve this, iron intake must be balanced with iron excretion by chelators to
prevent iron accumulation and end-organ complications and lead to normal survival and improved
quality of life. Therefore, appropriate tailoring of ICT with chelator choices and dose adjustments must
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be implemented in a timely manner. Moreover, the clinical decision to initiate, adjust and stop ICT is
based on SF, MRI-LIC and cardiac T2*.
Currently three iron chelators are widely available and used: deferoxamine (DFO) in subcutaneous
or intravenous injection; oral deferiprone (DFP) in tablet or solution form; and oral deferasirox (DFX),
in dispersible tablet (DT) and—more recently—film-coated tablet (FCT) forms [1,18,35]. While all three
of these drugs have proven their effectiveness as iron chelators in TDT patients, DFX remains the
only drug that has received Food and Drug Administration (FDA) and European Medicines Agency
(EMA) approval for use in NTDT patients, mostly based on results extracted and published from
the THALASSA trial [2,36]. In this multinational, prospective, randomized, double-blinded phase
II trial conducted on 148 patients comparing DFX (97 patients) to placebo (51 patients) [36], 1-year
treatment of NTDT patients older than 10 years was found to decrease LIC by a mean of 2.33 ± 0.70
and 4.18 ± 0.69 mg Fe/g dry weight at a daily dose of 5 and 10 mg/kg, respectively, compared to
placebo [36]. Sub-analyses further proved that irrespective of baseline LIC, SF, underlying NTDT form,
splenectomy status or demographics such as age, gender and race, both DFX 5 and 10 mg/kg/day
starting doses led to consistent reductions in LIC across all patients [36]. The analyses also showed
that greater reductions in LIC were achieved in patients dose-escalated at 6 months from DFX
10 mg/kg/day starting dose to 20 mg/kg/day [36]. There were no adverse effects noted in patients
who received DFX compared to placebo, and the only major side effects reported—mild to moderate
in severity, and self-resolving without drug discontinuation—were nausea/gastrointestinal discomfort
and headache [36]. A 1-year extension phase was then carried out to allow for the assessment of up to
2 years of DFX treatment. Patients continued to respond, with a decrease in LIC and SF over 2 years.
Data extracted from the THETIS study [37] further showed that a starting dose of 10 mg/kg/day of
DFX is effective in reducing iron overload in NTDT, and that dose escalation up to 30 mg/kg/day
should be considered starting at week 4 based on LIC response [37]. The THETIS analyses also
strengthened previous evidence concerning the safety profile of DFX while also providing insight
into its possible association with increased risk of pancreatitis and ocular toxicity [37]. DFP has not
been extensively studied in NTDT. Single-arm, open-label studies with small sample sizes and a more
recent randomized controlled trial showed significant decreases in SF and LIC with DFP therapy [38].
DFO has not been systematically studied in NTDT, although studies with small sample sizes and short
durations have shown an increase in urinary excretion of iron and a decrease in SF.
ICT is indicated for virtually all TDT patients receiving regular transfusions, but with NTDT,
specific indications have been established for its initiation, dose escalation and termination [1].
The Thalassemia International Federation (TIF) recommends that DFX chelation with initial starting
dose of 10 mg/kg/day should be started in patients ≥10 years of age (15 years of age in hemoglobin H
disease) if their LIC ≥5 mg Fe/g dry weight, or if their SF concentration was found to be ≥800 µg/L
when LIC is not available due to lack of the necessary MRI technology [1]. As for monitoring of iron
levels, LIC should be repeated 6 months after therapy initiation, with follow up every 6–12 months,
in addition to SF levels being measured every 3 months [1]. If at 6 months LIC is still >7 mg Fe/g dry
weight (or SF >1500 µg/L only if LIC is unavailable) with less than 15% reduction in baseline values,
dose escalation should be considered up to 20 mg/kg/day [1]. DFX therapy can be safely discontinued
when patients reach an LIC value of 3 mg Fe/g dry weight (or SF level of 300 µg/L only if LIC is
unavailable) [1]. In NTDT, it is recommended to intensify ICT if the LIC after 6 months of treatment
>7 mg/g dw. liver or SF >1500–2000 ng/mL and <15% decrease from baseline. Indications to stop ICT
in NTDT include a SF < 300 ng/mL and/or LIC < 3 mg/g dry wt. liver. Figure 2 portrays a screening,
diagnosis, and treatment algorithm for IOL in NTDT.
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6. Recent Advances in ICT
Compliance with ICT is associated with effective control of iron overload and improved patient
survival [39–41]. While iron chelation has proven itself as both a safe and effective for NTDT
patients, a major issue of compliance stands in the way of their successful management and ensuring
adherence in these patients should be of upmost priority [42]. The use of DFX dispersible tablets (DTs)
automatically implies several inconveniences to the patient including palatability, the need to take the
drug in a fasting state (i.e., not being able to take it with food), and drug-related side effects, notably
gastrointestinal (GI) tolerability [42]. These factors have created a barrier to optimal adherence to
DFX DTs, which has prompted the development of a new film-coated tablet (FCT) formulation [42].
This formulation can be swallowed once-daily, both whole or crushed, and regardless of whether the
patient is fasting or not [42]. The open-label, phase II ECLIPSE study also evaluated patient-reported
outcomes (PRO) in TDT or lower-risk myelodysplastic syndromes patients randomized to receive DFX
DT or FCT over a 24-week [42]. FCT recipients were uniformly more satisfied, and had fewer concerns
with the drug, and even reported better adherence and compliance, all while preserving the great
safety profile that DT formulations of DFX are well known for [42]. This new formulation provides a
promising alternative that would increase patient satisfaction and adherence, ensure better treatment
outcomes, and overall contribute to a better quality of life [42].
7. Novel Therapies
Newly emerging therapies targeting iron dysregulation include minihepcidins, transmembrane
protease serine 6 (TMPRSS6).
7.1. Minihepcidins
Minihepcidins, or long-acting hepcidin analogs, have been shown to restrict iron absorption,
and the r utilizatio in the setting of IOL has shown beneficial eff cts on ineffective ery hropoiesis [43–45].
They are known to i crease the levels of endogenous hepcidin, thereby decreasing iron absorpti n from
the GI tract, increasi g the redistribution of iron to macrophages, and lim ting end-organ toxicity [46].
Studies mice have also shown that minihepcidin therapy not nly increases Hb concentrations,
but also decreases reticulocyte counts nd reduces spleen size [46,47].
7.2. TMPRSS6
Encouraging preclinical data on transmembrane protease serine 6 (TMPRSS6) inhibitors have
also been recently reported, as an approach to stimulate endogenous hepcidin production [48–50].
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TMPRSS6 is a transmembrane serine protease that reduces production of hepcidin. Thus, endogenous
hepcidin production can be stimulated by reducing expression of TMPRSS6. Data from mouse models
suggest that deletion of the TMPRSS6 gene improves anaemia and reduces ineffective erythropoiesis,
splenomegaly, and iron loading [48]. Use of antisense oligonucleotides or small interfering RNAs
that target TMPRSS6 has been shown to improve anaemia and iron overload in mice and other
preclinical models of β-thalassaemia [49–51]. Genetic ablation of TMPRSS6 also improved ineffective
erythropoiesis and decreased splenomegaly in β-TI, without a concomitant decrease in erythropoietin
production [48]. Normalization of RBC survival is a significant component of the effects of TMPRSS6
inhibition on both hemoglobin and spleen size. The above-mentioned data on TMPRSS6 provide proof
of principle that pharmacologic manipulation of hepcidin may be an effective treatment for human
diseases of iron dysregulation.
8. Conclusions
In conclusion, IOL due to increased intestinal iron absorption represents an important clinical
problem in NTDT patients, particularly as they advance in age. Adequate assessment and monitoring
of NTDT patients, in addition to tailored ICT, is crucial for preventing the complications known to be
associated with this increased iron burden. New treatment modalities are currently being investigated
to broaden options available for NTDT management, with ultimate goals of prolonging longevity,
promoting greater compliance and better adherence and improving quality of life. Since NTDT patients
present with multiple pathophysiologies, tailoring treatment will always remain essential. Therefore,
future studies should aim at creating a validated tool that can be used to assess IOL severity and
tailor therapy, allowing for standardization of assessments that would lead to timely interventions and
prevention of IOL-related complications.
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